Trial · NCT00345865
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00345865, Phase 2, Completed, Masonic Cancer Center, University of Minnesota; results first posted 2020-07-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma. Trials, record NCT00345865. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00345865
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- NCT number
- NCT00345865
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 473 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine
- First posted
- 2006-06-29
- Last updated
- 2020-07-14
- Results first posted
- 2020-07-14
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With 1 Year Progression Free Survival | 1 year | Progression is defined using the Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group.The definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy. |
| Primary | Number of Participants With 2 Years Progression Free Survival | 2 years | Progression is determined using Response Criteria for Non-Hodgkin's Lymphoma given by NCI Sponsored International Working Group. Definition is as follows: At least a 50% increase from nadir of any previously identified abnormal node. Appearance of any new lesion during or at the end of therapy. |
| Primary | Number of Participants With 1 Year Overall Survival | 1 year | |
| Primary | Number of Participants With 2 Years Overall Survival | 2 years | |
| Secondary | Number of Participants With Hematopoietic Recovery After Transplantation | Day 42 | return to ANC (absolute neutrophil count) more than 500 cells/milliliter. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With 1 Year Progression Free Survival | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With 2 Years Progression Free Survival | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With 1 Year Overall Survival | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With 2 Years Overall Survival | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Hematopoietic Recovery After Transplantation | Day 42 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With 1 Year Progression Free Survival | NHL With Irradiation | 112 | Participants | ||
| Number of Participants With 1 Year Progression Free Survival | HL Without Irradiation | 102 | Participants | ||
| Number of Participants With 1 Year Progression Free Survival | NHL - HIV Infected With Irradiation | 1 | Participants | ||
| Number of Participants With 1 Year Progression Free Survival | NHL - HIV Infected Without Irradiation | 2 | Participants | ||
| Number of Participants With 1 Year Progression Free Survival | NHL Without Radiation and Cyclophosphamide | 116 | Participants | ||
| Number of Participants With 2 Years Progression Free Survival | NHL With Irradiation | 96 | Participants | ||
| Number of Participants With 2 Years Progression Free Survival | HL Without Irradiation | 91 | Participants | ||
| Number of Participants With 2 Years Progression Free Survival | NHL - HIV Infected With Irradiation | 1 | Participants | ||
| Number of Participants With 2 Years Progression Free Survival | NHL - HIV Infected Without Irradiation | 1 | Participants | ||
| Number of Participants With 2 Years Progression Free Survival | NHL Without Radiation and Cyclophosphamide | 106 | Participants |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | NHL With Irradiation | 171 | |
| Overall Study | STARTED | HL Without Irradiation | 149 | |
| Overall Study | STARTED | NHL - HIV Infected With Irradiation | 2 | |
| Overall Study | STARTED | NHL - HIV Infected Without Irradiation | 5 | |
| Overall Study | STARTED | NHL Without Radiation and Cyclophosphamide | 146 | |
| Overall Study | COMPLETED | NHL With Irradiation | 171 | |
| Overall Study | COMPLETED | HL Without Irradiation | 149 | |
| Overall Study | COMPLETED | NHL - HIV Infected With Irradiation | 2 | |
| Overall Study | COMPLETED | NHL - HIV Infected Without Irradiation | 5 | |
| Overall Study | COMPLETED | NHL Without Radiation and Cyclophosphamide | 146 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events110
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Infection | Infections and infestations | NHL With Irradiation | 94 | 171 | 331 |
| other | Infection | Infections and infestations | HL Without Irradiation | 63 | 149 | 187 |
| other | Infection | Infections and infestations | NHL - HIV Infected With Irradiation | 1 | 2 | 1 |
| other | Infection | Infections and infestations | NHL - HIV Infected Without Irradiation | 2 | 5 | 15 |
| other | Infection | Infections and infestations | NHL Without Radiation and Cyclophosphamide | 103 | 146 | 291 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | NHL With Irradiation | 67 | 171 | 160 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | HL Without Irradiation | 53 | 149 | 102 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | NHL - HIV Infected With Irradiation | 1 | 2 | 1 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | NHL - HIV Infected Without Irradiation | 2 | 5 | 6 |
| other | Pneumonia | Respiratory, thoracic and mediastinal disorders | NHL Without Radiation and Cyclophosphamide | 55 | 146 | 102 |
1 to 10 of 110Source ClinicalTrials.gov
See all 110 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | NHL With Irradiation | 47 | 171 |
| Total, all-cause mortality | HL Without Irradiation | 9 | 149 |
| Total, all-cause mortality | NHL - HIV Infected With Irradiation | 1 | 2 |
| Total, all-cause mortality | NHL - HIV Infected Without Irradiation | 1 | 5 |
| Total, all-cause mortality | NHL Without Radiation and Cyclophosphamide | 25 | 146 |
| Total, other adverse events | NHL With Irradiation | 125 | 171 |
| Total, other adverse events | HL Without Irradiation | 98 | 149 |
| Total, other adverse events | NHL - HIV Infected With Irradiation | 2 | 2 |
| Total, other adverse events | NHL - HIV Infected Without Irradiation | 2 | 5 |
| Total, other adverse events | NHL Without Radiation and Cyclophosphamide | 120 | 146 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00345865
GET https://conductscience.org/api/trials/v1/NCT00345865/results?page=2